| Year |
Citation |
Score |
| 2022 |
Strauss MJ, Porter KD, Quizon PM, Davis SE, Lin S, Yuan Y, Martinez-Muniz GA, Sun WL, Zhan CG, Zhu J. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function. Plos One. 17: e0275182. PMID 36170295 DOI: 10.1371/journal.pone.0275182 |
0.674 |
|
| 2022 |
Zhu J, Quizon PM, Wang Y, Adeniran CA, Strauss MJ, Torres AJ, Patel P, Cirino TJ, Eans SO, Hammond HR, Deliscar LS, O'Hara P, Saini SK, Ofori E, Vekariya RH, et al. SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice. Neuropharmacology. 109239. PMID 36126727 DOI: 10.1016/j.neuropharm.2022.109239 |
0.675 |
|
| 2021 |
Quizon PM, Yuan Y, Zhu Y, Zhou Y, Strauss MJ, Sun WL, Zhan CG, Zhu J. Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. PMID 33537927 DOI: 10.1007/s11481-021-09984-5 |
0.731 |
|
| 2020 |
Strauss M, O'Donovan B, Ma Y, Xiao Z, Lin S, Bardo MT, Ortinski PI, McLaughlin JP, Zhu J. [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Tat Protein. The Journal of Pharmacology and Experimental Therapeutics. PMID 32461322 DOI: 10.1124/Jpet.120.266023 |
0.734 |
|
| 2019 |
Sun WL, Quizon PM, Yuan Y, Strauss MJ, McCain R, Zhan CG, Zhu J. Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport. Scientific Reports. 9: 3843. PMID 30846720 DOI: 10.1038/S41598-019-39872-1 |
0.717 |
|
| Show low-probability matches. |